A recent study found that STOML2 promotes the viability and motility of breast cancer cells in vitro by mediating FOXO3a expression and the extracellular signal-regulated kinase (ERK) pathway, indicating its potential as a therapeutic target for breast cancer [71]. This evidence concerns the gene FOXO3 and breast carcinoma.